| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 24 Feb 2026 | 17 Feb 2026 |
| Healthcare Global Enterprises Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/02/2026 inter alia to consider and approve various matters in connection with the Rights Issue as approved by the Board on February 17 2026 including the specific terms of the Rights Issue such as the determination of the Rights Issue price and related payment mechanism rights entitlement ratio the record date and timing of the Rights Issue and other related matters subject to the receipt of in-principle approval from the stock exchanges where the securities of the Company are listed or such other regulatory authorities as may be required. The Board of Directors of the Company at its meeting held today, February 24, 2026, has decided to issue equity shares on rights basis in the ratio of 1:17 (1 Rights Equity Share for every 17 fully paid-up equity shares) held on the record date being March 02, 2026, at an Issue Price of Rs. 512 per share. (As Per BSE Announcement Dated on 24.02.2026) | ||
| Board Meeting | 17 Feb 2026 | 8 Feb 2026 |
| Healthcare Global Enterprises Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/02/2026 ,inter alia, to consider and approve the proposal of fund raise by way of issuance of equity shares through Rights Issue. Healthcare Global Enterprises Limited has informed the Exchange regarding Outcome of Board Meeting held on February 17, 2026, with respect to the approval received from the Board of Directors of the Company, for the issuance of fully paid-up equity shares of the Company of face value of INR 10 each for an amount not exceeding INR 42,500 Lakhs (Rupees Forty Two Thousand and Five Hundred Lakhs) by way of a rights issue to the eligible equity shareholders of the Company as on the record date (to be determined and notified subsequently), in accordance with applicable laws, including the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, subject to such regulatory and statutory approvals, as may be required under the applicable laws. (As Per BSE Announcement Dated on:17.02.2026) | ||
| Board Meeting | 5 Feb 2026 | 23 Jan 2026 |
| Healthcare Global Enterprises Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 ,inter alia, to consider and approve This is to inform that a meeting of the Board of Directors of the Company will be held on Thursday, February 05, 2026, at the Corporate Office of the Company at No. 3, Tower Block, Unity Building Complex, Mission Road, Bengaluru - 560027, inter-alia to consider, approve and take on record the Unaudited Financial Results (both Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2025. This is to inform that the Board of Directors of the Company at its meeting held on February 05, 2026, has, inter alia, considered and approved the following agenda: 1. Unaudited Financial Results of the Company (Standalone and Consolidated), for the quarter and nine months ended December 31, 2025. 2. Introduction and adoption of HCG Employee Stock Option Scheme, 2026, to grant Employee Stock Options to Eligible Employees of the Company and its subsidiaries, subject to approval of Members of the Company and other requisite regulatory or statutory approvals, as may be applicable. Detailed disclosure in this regard shall be made separately. 3. Appointment of Dr. Naveen R. Nagar as Head - Clinical Strategy and Mr. Pankaj Gautam as Chief Information Officer, designated as Senior Management Personnel of the Company. Detailed disclosure in this regard shall be made separately. | ||
| Board Meeting | 1 Dec 2025 | 1 Dec 2025 |
| Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that, based on the recommendation of the Audit Committee and the Nomination and Remuneration Committee, the Board of Directors of the Company, at its meeting held on December 01, 2025 has approved the appointment of Dr. Manish Mattoo, Executive Director and Chief Executive Officer, as the interim Chief Financial Officer and Key Managerial Personnel of the Company in accordance with Section 203 of the Companies Act, 2013. The appointment shall be effective from December 01, 2025, and shall remain in force until a new CFO is appointed by the Board of Directors and assumes office as the CFO. | ||
| Board Meeting | 12 Nov 2025 | 5 Nov 2025 |
| Healthcare Global Enterprises Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 inter alia to consider and approve This is to inform that a meeting of the Board of Directors of the Company will be held on Wednesday November 12 2025 at the Corporate Office of the Company at No. 3 Tower Block Unity Building Complex Mission Road Bengaluru - 560027 inter-alia to consider approve and take on record the Unaudited Financial Results (both Standalone and Consolidated) of the Company for the quarter and six months ended September 30 2025 (Financial Results). Approval of unaudited financial results of the Company (Standalone and Consolidated), for the quarter and six months ended September 30, 2025. Acquisition of up to 10% equity stake in Cancer Care Kenya Limited, step-down subsidiary of the Company in Kenya. Issuance of guarantee in the form of Standby Letter of Credit (SBLC) to secure credit facilities proposed to be availed by Cancer Care Kenya Limited, step-down subsidiary of the Company in Kenya for its business expansion. Read less.. (As Per BSE Announcement Dated on 12.11.2025) | ||
| Board Meeting | 1 Aug 2025 | 7 Jul 2025 |
| Quarterly Results Healthcare Global Enterprises Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2025 ,inter alia, to consider and approve Healthcare Global Enterprises Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2025,inter alia, to consider and approve Unaudited Financial Results (both Standalone and Consolidated) of the Company for the quarter ended June 30, 2025 (As per BSE Announcement Dated on 07/07/2025) The Board of Directors of the Company at its meeting held on August 01, 2025, has, inter-alia, considered and approved the Unaudited Financial Results of the Company (Standalone and Consolidated), for the quarter ended June 30, 2025 The Board of Directors of the Company at its meeting held on August 01, 2025, has, inter-alia, considered and approved appointment of M/s. V Sreedharan and Associates, Practicing Company Secretaries, as Secretarial Auditors of the Company for a term of five (5) consecutive years commencing from the conclusion of the AGM to be held in FY 2025-26 and Re-appointment of M/s Rao Murthy and Associates, Cost Accountants as Cost Auditor of the Company for the financial year 2025-26 (As per BSE Announcement Dated on 01/08/2025) | ||
| Board Meeting | 24 May 2025 | 12 May 2025 |
| Healthcare Global Enterprises Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2025 inter alia to consider and approve Audited Financial Results (both Standalone and Consolidated) of the Company for the quarter and year ended March 31 2025 (Audited Financial Results). The Board of Directors of the Company at its meeting held on May 24, 2025 has considered and approved the Audited Financial Results (Standalone and Consolidated) for quarter and year ended March 31, 2025. (As Per BSE Announcement Dated on :24.05.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
